Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 09 2020 - 8:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2020
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
16 Tiomkin St.
Tel Aviv 6578317, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Attached hereto and
incorporated herein by reference is a press release, dated November 9, 2020, and entitled “Galmed and MyBiotics to Collaborate
in Development of Bespoke Microbiome Signature for Aramchol”.
The first two
paragraphs and “Forward Looking Statements” of the press release attached to this Form 6-K are incorporated by
reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292
and 333-227441) and the
Company’s Registration Statement on Form F-3 (Registration No. 333-223923).
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd.
|
|
|
|
Date: November 9, 2020
|
By:
|
/s/ Allen Baharaff
|
|
|
Allen Baharaff
|
|
|
President and Chief Executive Officer
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Apr 2024 to May 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From May 2023 to May 2024